Mesenchymal stromal cells and uses related thereto

Abstract

The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and method sof treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

1 . A pharmaceutical preparation, comprising at least 10 6  mesenchymal stromal cells, wherein CD24 expression is upregulated in mesenchymal stromal cells of the preparation, as compared to mesenchymal stromal cells of bone marrow, and wherein mRNA encoding interleukin-6 (IL-6) is expressed in mesenchymal stromal cells of the preparation at a level that is less than ten percent of the IL-6 mRNA level expressed by mesenchymal stromal cells of bone marrow. 
     
     
         2 - 45 . (canceled) 
     
     
         46 . A method for generating mesenchymal stromal cells comprising
 culturing embryonic stem cells under conditions that give rise to a mesenchymal stromal cell population, wherein CD24 expression is upregulated in mesenchymal stromal cells of the population, as compared to mesenchymal stromal cells of bone marrow, and wherein mRNA encoding interleukin-6 (IL-6) is expressed in mesenchymal stromal cells of the population at a level that is less than ten percent of the IL-6 mRNA level expressed by mesenchymal stromal cells of bone marrow; and   isolating the mesenchymal stromal cell population.   
     
     
         47 - 102 . (canceled) 
     
     
         103 . A kit comprising the preparation of mesenchymal stromal cells of  claim 1 . 
     
     
         104 - 125 . (canceled) 
     
     
         126 . The pharmaceutical preparation of  claim 1  further comprising a pharmaceutically acceptable carrier. 
     
     
         127 . The pharmaceutical preparation of  claim 1 , wherein the mesenchymal stromal cells are HLA-genotypically identical or genomically identical. 
     
     
         128 . The pharmaceutical preparation of  claim 1 , wherein at least 50% of the mesenchymal stromal cells of the preparation are positive for CD24 expression. 
     
     
         129 . The pharmaceutical preparation of  claim 1 , wherein the preparation retains between 50% and 100% of its proliferative capacity after ten population doublings. 
     
     
         130 . The pharmaceutical preparation of  claim 1 , wherein the preparation is pyrogen-free and/or pathogen-free. 
     
     
         131 . The pharmaceutical preparation of  claim 1 , wherein the mesenchymal stromal cells are generated in vitro from pluripotent cells. 
     
     
         132 . The pharmaceutical preparation of  claim 131 , wherein the pluripotent cells are embryonic stem cells or induced pluripotent stem cells. 
     
     
         133 . The pharmaceutical preparation of  claim 1 , wherein the mesenchymal stromal cells are isolated at early passage. 
     
     
         134 . The pharmaceutical preparation of  claim 133 , wherein the mesenchymal stromal cells have a replicative capacity to undergo at least 10 population doublings in cell culture in less than 25 days. 
     
     
         135 . The pharmaceutical preparation of  claim 1 , wherein the mesenchymal stromal cells express lower Stro-1 expression levels, relative to mesenchymal stromal cells derived from bone marrow. 
     
     
         136 . The pharmaceutical preparation of  claim 1 , wherein the preparation comprises less than 1% pluripotent stem cells. 
     
     
         137 . The pharmaceutical preparation of  claim 136 , wherein the preparation is devoid of pluripotent stem cells. 
     
     
         138 . The pharmaceutical preparation of  claim 1 , wherein at least 90% of cells of the preparation are mesenchymal stromal cells. 
     
     
         139 . The pharmaceutical preparation of  claim 1 , wherein the pharmaceutical preparation comprises an effective amount of the mesenchymal stromal cells to treat an autoimmune disease, an inflammatory disease, pain, heat sensitivity or cold sensitivity. 
     
     
         140 . The pharmaceutical preparation of  claim 139 , wherein the pharmaceutical preparation comprises an effective amount of the mesenchymal stromal cells to treat an autoimmune disease selected from multiple sclerosis, refractory systemic lupus erythematosus, lupus nephritis and Crohn's disease. 
     
     
         141 . The pharmaceutical preparation of  claim 139 , wherein the pharmaceutical preparation comprises an effective amount of the mesenchymal stromal cells to treat uveitis. 
     
     
         142 . The pharmaceutical preparation of  claim 139 , wherein the pharmaceutical preparation comprises an effective amount of the mesenchymal stromal cells to treat pain.